Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

作者：Harry G.M. Heijerman, Edward F. McKone, Damian G. Downey, Eva Van Braeckel, Steven Mark Rowe, Elizabeth D. Tullis, Marcus Alexander Mall, John J Welter, Bonnie W. Ramsey, Charlotte M. McKee, Gautham Marigowda, Samuel M. Moskowitz, David Waltz, Patrick R. Sosnay, Christopher Simard, Neil Ahluwalia, Fengjuan Xuan, Yaohua Zhang, Jennifer L. Taylor‐Cousar, Karen McCoy, Karen McCoy, Scott H. Donaldson, Seth D. Walker, James F. Chmiel, Ronald C. Rubenstein, Deborah K. Froh, Isabel P. Neuringer, Manu Jain, Kathryn S. Moffett, Jennifer L. Taylor‐Cousar, Bruce Barnett, Gary A. Mueller, Patrick A. Flume, Floyd R. Livingston, Nighat Mehdi, Charlotte C. Tenebäck, John J Welter, Raksha Jain, Dana G. Kissner, K. Patel, Francisco J. Calimano, Jimmy Johannes, Cori L. Daines, Thomas G. Keens, Herschel Scher, Subramanyam Chittivelu, Sudhakar Reddivalam, Ross C. Klingsberg, Larry G. Johnson, Stijn L. Verhulst, Patricia Macedo, Damian G. Downey, Gary James Connett, Edward Fairbairn Nash, Nicholas Withers, Timothy T. Lee, Marleen Bakker, Harry G.M. Heijerman, François L. Vermeulen, Eva Van Braeckel, Christiane Knoop, Elke De Wachter, Renske van der Meer, Petrus Merkus, Christof J. Majoor · 发表于：The Lancet · 年份：2019 · DOI：10.1016/s0140-6736(19)32597-8 · 被引用次数：1424 · 研究领域：Cystic Fibrosis Research Advances、Delphi Technique in Research、Neonatal Respiratory Health Research